These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 17009312)

  • 21. Food and Drug Administration Drug Approval Process: A History and Overview.
    Williams CT
    Nurs Clin North Am; 2016 Mar; 51(1):1-11. PubMed ID: 26897420
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Biopharmaceutical statistics in a pharmaceutical regulated environment: past, present, and future.
    Segreti AC; Leung HM; Koch GG; Davis RL; Mohberg NR; Peace KE
    J Biopharm Stat; 2001 Nov; 11(4):347-72. PubMed ID: 12018784
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The courage of one's convictions: the due diligence of Frances Oldham Kelsey at the FDA.
    Scheindlin S
    Mol Interv; 2011 Feb; 11(1):3-9. PubMed ID: 21441115
    [No Abstract]   [Full Text] [Related]  

  • 24. The cosmetic/drug dilemma: FDA regulation of alpha-hydroxy acids.
    Heymann LA
    Food Drug Law J; 1997; 52(4):357-75. PubMed ID: 10346670
    [No Abstract]   [Full Text] [Related]  

  • 25. The right to a trial: Should dying patients have access to experimental drugs?
    Groopman J
    New Yorker; 2006 Dec; ():40-7. PubMed ID: 17176539
    [No Abstract]   [Full Text] [Related]  

  • 26. A history of drugs on the weight list.
    Dolgin E
    Nat Med; 2012 Jun; 18(6):843. PubMed ID: 22673985
    [No Abstract]   [Full Text] [Related]  

  • 27. FDA: today's strengths built on turbulent past.
    Small WE
    Am Pharm; 1980 Jan; NS20(1):25-7. PubMed ID: 6989223
    [No Abstract]   [Full Text] [Related]  

  • 28. Fifty Years of Expert Advice - Pharmaceutical Regulation and the Legacy of the Drug Efficacy Study.
    Schwartz JL
    N Engl J Med; 2016 Nov; 375(21):2015-2017. PubMed ID: 27959733
    [No Abstract]   [Full Text] [Related]  

  • 29. The Food and Drug Administration's use of postmarketing (Phase IV) study requirements: exception to the rule?
    Steenburg C
    Food Drug Law J; 2006; 61(2):295-383. PubMed ID: 16903034
    [No Abstract]   [Full Text] [Related]  

  • 30. Pharmacometrics at FDA: evolution and impact on decisions.
    Powell JR; Gobburu JV
    Clin Pharmacol Ther; 2007 Jul; 82(1):97-102. PubMed ID: 17538553
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Losing deference in the FDA's second century: judicial review, politics, and a diminished legacy of expertise.
    O'Reilly JT
    Cornell Law Rev; 2008 Jul; 93(5):939-80. PubMed ID: 18618965
    [No Abstract]   [Full Text] [Related]  

  • 32. Sam Greenhouse: his contributions as a consultant to the Food and Drug Administration.
    O'Neill RT
    Stat Med; 2003 Nov; 22(21):3285-9. PubMed ID: 14566912
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The new Food and Drug Administration drug package insert: implications for patient safety and clinical care.
    Watson KT; Barash PG
    Anesth Analg; 2009 Jan; 108(1):211-8. PubMed ID: 19095852
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Commemorating the 50th anniversary of the Drug Amendments of 1962.
    Hutt PB; Temple R
    Food Drug Law J; 2013; 68(4):449-65. PubMed ID: 24552082
    [No Abstract]   [Full Text] [Related]  

  • 35. Frances Kelsey honored for FDA legacy: award notes her work on thalidomide, clinical trials.
    Kuehn BM
    JAMA; 2010 Nov; 304(19):2109-10, 2112. PubMed ID: 21081717
    [No Abstract]   [Full Text] [Related]  

  • 36. Changing requirements for evaluation of pharmacologic agents.
    Chesney RW; Christensen ML
    Pediatrics; 2004 Apr; 113(4 Suppl):1128-32. PubMed ID: 15060209
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Laetrile in historical perspective.
    Kardinal CG
    Mo Med; 1980 Sep; 77(9):564-9. PubMed ID: 7001210
    [No Abstract]   [Full Text] [Related]  

  • 38. The FDA and deference lost: a self-inflicted wound or the product of a wounded agency? A response to Professor O'Reilly.
    Vladeck DC
    Cornell Law Rev; 2008 Jul; 93(5):981-1002. PubMed ID: 18618967
    [No Abstract]   [Full Text] [Related]  

  • 39. The challenges of globalization in pharmaceutical law--is an international drug approval system modeled after the European system worth considering?
    Purnhagen KP
    Food Drug Law J; 2008; 63(3):623-45. PubMed ID: 19031663
    [No Abstract]   [Full Text] [Related]  

  • 40. The cancer "cures": a challenge to rational therapeutics.
    Janssen WF
    Anal Chem; 1978 Feb; 50(2):197A-202A. PubMed ID: 341747
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.